One Biosciences & AP-HP Collaborate on Rare Kidney Disease Study-HP

One Biosciences is a biotech company that utilizes the capabilities of single-cell analysis and artificial intelligence (A.I.) to drive its research and development efforts. A new partnership has been formed with Assistance Publique - Hôpitaux de Paris (AP-HP), a group of hospitals in the greater Paris region, to conduct research on kidney disease in order to discover new precision medicine targets and treatments for the next generation. This disease is marked by a progressive decline in kidney function and currently lacks a viable treatment option.

Transplantation is often the only choice, despite frequent relapses. One Biosciences will have the opportunity to utilize anonymized patient samples and clinical data from four of AP-HP's hospitals (Hôpital Tenon, Hôpital Necker, Hôpital Kremlin-Bicêtre, Hôpitaux Universitaires Henri-Mondor) as part of the research partnership. One Biosciences plans to use the data to find new therapeutic targets for this uncommon kidney disease, with the goal of creating precise medications and biomarkers to detect disease relapse through its discovery platform. One Biosciences utilizes a cutting-edge discovery engine that integrates artificial intelligence and single-cell technologies. This comprehensive platform includes a range of single-cell protocols and exclusive computational solutions, all of which adhere to the strictest standards of patient health data privacy and security. Once more, this partnership reaffirms the robustness of the French innovation ecosystem in biotech and the collaborative synergies being created among its participants. We are excited to announce that One Biosciences and AP-HP are teaming up at Biolabs Hôtel Dieu to speed up the investigation of a rare kidney disease, with the goal of discovering biomarkers and potential treatment options for patients who currently lack effective care.